276 related articles for article (PubMed ID: 18614429)
41. Ocular bioerodible minitablets as strategy for the management of microbial keratitis.
Weyenberg W; Vermeire A; Dhondt MM; Adriaens E; Kestelyn P; Remon JP; Ludwig A
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3229-33. PubMed ID: 15326145
[TBL] [Abstract][Full Text] [Related]
42. Bioequivalence of two oral formulations of glyburide (glibenclamide).
Flores-Murrieta FJ; Carrasco-Portugal Mdel C; Reyes-García G; Medina-Santillán R; Herrera JE
Proc West Pharmacol Soc; 2007; 50():64-6. PubMed ID: 18605232
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
Washington CB; Hou SY; Campanella C; Hughes N; Brown S; Berner B
J Clin Pharmacol; 2005 Nov; 45(11):1236-44. PubMed ID: 16239356
[TBL] [Abstract][Full Text] [Related]
44. A bioequivalence study of two brands of glipizide tablets.
Kobylińska M; Bukowska-Kiliszek M; Barlińska M; Sobik B; Kobylińska K
Acta Pol Pharm; 2000; 57(2):101-4. PubMed ID: 10934787
[TBL] [Abstract][Full Text] [Related]
45. Bioavailability of ciprofloxacin tablets in humans and its correlation with the dissolution rates.
Khan MK; Khan MF; Khan H; Mustafa G
Pak J Pharm Sci; 2009 Jul; 22(3):329-34. PubMed ID: 19553184
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers.
Escobar Y; Hoyo-Vadillo C
Arzneimittelforschung; 2003; 53(9):664-7. PubMed ID: 14558441
[TBL] [Abstract][Full Text] [Related]
48. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.
Bagli M; Höflich G; Rao ML; Langer M; Baumann P; Kolbinger M; Barlage U; Kasper S; Möller HJ
Int J Clin Pharmacol Ther; 1995 Dec; 33(12):646-52. PubMed ID: 8963481
[TBL] [Abstract][Full Text] [Related]
49. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
50. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
51. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
[TBL] [Abstract][Full Text] [Related]
52. Ciprofloxacin and norfloxacin pharmacokinetics and prostatic fluid penetration in dogs after multiple oral dosing.
Albarellos GA; Montoya L; Waxman S; Kreil V; Ambros LA; Hallu R; Rebuelto M
Vet J; 2006 Sep; 172(2):334-9. PubMed ID: 15994101
[TBL] [Abstract][Full Text] [Related]
53. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs.
Bidgood TL; Papich MG
J Vet Pharmacol Ther; 2005 Aug; 28(4):329-41. PubMed ID: 16050812
[TBL] [Abstract][Full Text] [Related]
54. [Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide].
Vergin H; Bishop-Freudling GB; Strobel K; Reeves DS
Arzneimittelforschung; 1983; 33(3):458-62. PubMed ID: 6683523
[TBL] [Abstract][Full Text] [Related]
55. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes.
Akkan AG; Mutlu I; Ozyazgan S; Gök A; Yigit U; Ozüner Z; Senses V; Pekel H
Int J Clin Pharmacol Ther; 1997 May; 35(5):214-7. PubMed ID: 9174877
[TBL] [Abstract][Full Text] [Related]
56. Comparative bioavailability of two brands of ciprofloxacin: an Indian study.
Suthakaran C; Rajaram S; Adithan C
Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):66-8. PubMed ID: 1551749
[TBL] [Abstract][Full Text] [Related]
57. Comparative bioavailability of norfloxacin tablets based on blood and urine data.
Nada AH; Sharaf MA; El Gholmy ZA; Khalafallah NM
Med Princ Pract; 2007; 16(6):426-31. PubMed ID: 17917441
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.
Ding HZ; Yang GX; Huang XH; Chen ZL; Zeng ZL
J Vet Pharmacol Ther; 2008 Jun; 31(3):200-4. PubMed ID: 18471140
[TBL] [Abstract][Full Text] [Related]
59. [Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers].
Huang T; Li T; Yang L; Xu X; Zheng P; Zhang T; Zheng J; Chen S
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Apr; 24(2):376-8. PubMed ID: 17591264
[TBL] [Abstract][Full Text] [Related]
60. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
Lipman J; Gous AG; Mathivha LR; Tshukutsoane S; Scribante J; Hon H; Pinder M; Riera-Fanego JF; Verhoef L; Stass H
Intensive Care Med; 2002 Apr; 28(4):493-500. PubMed ID: 11967606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
